Rifampin protects human lung epithelial cells against cytotoxicity induced by clinical multi and pandrug-resistant Acinetobacter baumannii

Journal of Infectious Diseases

Volumn 203, Issue 8, 2011, Pages 1110-1119

  Smani, Younes ^a   Domínguez Herrera, Juan ^a   Pachón, Jerónimo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; INTERLEUKIN 6; RIFAMPICIN; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CELL DAMAGE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; CYTOTOXICITY; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PANDRUG RESISTANCE; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; APOPTOSIS; CELL LINE, TUMOR; CULTURE MEDIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPITHELIAL CELLS; HUMANS; LUNG; OXIDATIVE STRESS; RIFAMPIN;

EID: 79953308452     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq159     Document Type: Article

References (50)

1. Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother 2008; 9:587-99. (Pubitemid 351425386)
2. Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54:1165-72.
3. Tripodi MF, Durante-Magoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ ampicillin alone or in combination against multidrug-resistant Acinetobacter baumannii isolates OXA-58 carbapenemases. Int J Antimicrob Agents 2007; 30:537-40. (Pubitemid 350051770)
4. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53:274-8. (Pubitemid 44391062)
5. Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61:417-20.
6. Petrosillo N, Chinello P, Proietti MF, et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005; 11:682-3. (Pubitemid 41051389)
7. Blanchard JS. The ying and yang of rifampicin. Nat Med 1998; 14:14-5. (Pubitemid 28133068)
8. Gil D, Garcia LF, Rojas M. Modulation of macrophage apoptosis by antimycobacterial therapy: physiological role of apoptosis in the control of Mycobacterium tuberculosis. Toxicol Appl Pharmacol 2003; 190:111-9. (Pubitemid 36870879)
9. Mlambo G, Sigola LB. Rifampicin and dexamethasone have similar effects on macrophage phagocytosis of zymosan, but differ in their effects on nitrite and TNF-α production. Int Immunopharmacol 2003; 3:513-22. (Pubitemid 36419512)
10. Pahlevan AA, Wright DJ, Bradley L, Smith C, Foxwell BM. Potential of rifamides to inhibit TNF-induced NF-kappaB activation. J Antimicrob Chemother 2002; 49:531-4. (Pubitemid 34223675)
11. Tentori L, Graziani G, Porcelli SA, et al. Rifampin increases cytokineinduced express molecule in human peripheral blood monocytes. Antimicrob Agents Chemother 1998; 42:550-4. (Pubitemid 28114807)
12. Ziglam HM, Daniels I, Finch RG. Immunomodulating activity of rifampicin. J Chemother 2004; 16:357-61. (Pubitemid 39049886)
13. Yuhas Y, Berent E, Ovadiah H, Azoulay I, Ashkenazi S. Rifampin augments cytokine-induced nitric oxide production in human alveolar epithelial cells. Antimicrob Agents Chemother 2006; 50:396-8. (Pubitemid 43042957)
14. Yulug B, Kilic U, Kilic E, Bähr M. Rifampicin attenuates brain damage in focal ischemia. Brain Res 2004; 996:76-80. (Pubitemid 37510296)
15. Tomiyama T, Asano S, Suwa Y, et al. Rifampicin prevents the aggregation and neurotoxicity of amyloid β protein in vitro. Biochem Biophys Res Commun 1994; 204:76-83. (Pubitemid 24335264)
16. Tomiyama T, Shoji A, Kataoka K, et al. Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin. J Biol Chem 1996; 271:6839-45.
17. Kilic U, Kilic E, Lingor P, Yulug B, Bahr M. Rifampicin inhibits neurodegeneration in the optic nerve transaction model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro. Acta Neuropathol (Berl) 2004; 108:65-8. (Pubitemid 38961075)
18. Xu J, Wei C, Xu C, et al. Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-Synuclein multimer. Brain Res 2007; 1139:220-5.
19. Oida Y, Kitaichi K, Nakayama H, et al. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain. Brain Res 2006; 1082:196-204.
20. Calleja C, Pascussi JM, Mani JC, Maurel P, Vilarem MJ. The antibiotic rifampicin is a non-steroidal ligand and activator of the human glucocorticoid receptor. Nat Med 1998; 4:92-6. (Pubitemid 28133086)
21. Yuhas Y, Azoulay-Alfaguter I, Berent E, Ashkenazi S. Rifampin inhibits PGE2 production and arachidonic acid release in human alveolar epithelial cells. Antimicrob Agents Chemother 2007; 5:4225-30. (Pubitemid 350209869)
22. Scoltock AB, Heimlich G, Cidlowski JA. Glucocorticoids inhibit the apoptotic actions of UV-C but not Fas ligand in hepatoma cells: direct evidence for a critical role of Bcl-Xl. Cell Death Differ 2007; 14:840-50. (Pubitemid 46444521)
23. Lüthi A, Martin SJ. The CASBAH: a searchable database of caspase substrates. Cell Death Differ 2007; 14:641-50. (Pubitemid 46444502)
24. Beg AA, Baltimore D. An essential role for NF-kappaB preventing TNF-alpha-induced cell death. Science 1996; 274:782-4. (Pubitemid 26398258)
25. Yerramasetti R, Gollapudi S, Gupta S. Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol 2002; 22:37-47. (Pubitemid 34203127)
26. Gollapudi S, Jaidka S, Gupta S. Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPS. J Clin Immunol 2003; 23:11-22. (Pubitemid 36207973)
27. Nau R, Wellmer A, Soto A, et al. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J Infect Dis 1999; 179:1557-60. (Pubitemid 29246610)
28. Böttcher T, Gerber J, Wellmer A, et al. Rifampicin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J Infect Dis 2000; 181:2095-8. (Pubitemid 30416184)
29. Gerber J, Pohl K, Sander V, Bunkowski S, Nau R. Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone. Antimicrob Agents Chemother 2003; 47:1313-7. (Pubitemid 36368591)
30. Speer A, Lugert R, Stoltefaut V, Hoecht A, Eiffert H, Nau R. Short-term rifampicin pre-treatment reduces inflammation and neuronal cell death in a rabbit model of bacterial meningitis. Crit Care Med 2009; 37:2253-8.
31. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard. NCCLS document M7-A6. Wayne, PA: NCCLS, 2003.
32. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. Wayne, PA: CLSI, 2006.
33. National Committee for Clinical Laboratory Standards (NCCLS). Methods for determining bactericidal activity of antimicrobial agents. Approved standard M26-A. Wayne, PA: NCCLS, 1999.
34. Gurr JR, Wang ASS, Chen CH, Jan KY. Ultrafine titanium dioxide particles in the absence of photoactivation can induce oxidative damage to human bronchial epithelial cells. Toxicology 2005; 213:66-73. (Pubitemid 41191282)
35. Smani Y, Fifre A, Labrude P, Vigneron C, Faivre B. Pharmacological and physicochemical factors in the pressor effects of conjugated haemoglobin-based oxygen carriers in vivo. J Hypert 2007; 25: 599-608. (Pubitemid 46213799)
36. LaPlante KL, Woodmansee S. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother 2009; 53:3880-6.
37. Alarcón T, López-Hernández S, Andreu D, Saugar JM, Rivas L, López-Brea M. In vitro activity of CA(1-8)M(1-18), a synthetic cecropin A-melittin hybrid peptide, against multiresistant Acinetobacter baumannii strains. Rev Esp Quimioter 2001; 14:184-90.
38. Smani Y, Fernández-Cuenca F, Docobo-Pérez F, et al. Attenuated virulence of a pan-drug resistant clone of Acinetobacter baumannii (PDRAb) is associated with decreased expression of the outer membrane proteins (OMPs) CarO and OprD-like [abstract P7]. In: Acinetobacter 2010 8th International Symposium on the Biology of Acinetobacter (Rome). Rome, Italy, 2010.
39. Murillo O, Pachón ME, Euba G, et al. Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection. Antimicrob Agents Chemother 2008; 52:3681-6.
40. Appleman MD, Belzberg H, Citron DM, et al. In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob Agents Chemother 2000; 44:1035-40.
41. Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus betalactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46:1946-52. (Pubitemid 34535219)
42. Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 2009; 33:33-9.
43. Wolff M, Joly-Guillou ML, Farinotti R, Carbon C. In vivo efficacies of combinations of β-lactams, β-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 1999; 43:1406-11.
44. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001; 40:117-20. (Pubitemid 32735549)
45. Rojanasakul Y, Shi X, Deshpande D, Liang WW, Wang LY. Protection against oxidative injury and permeability alteration in cultured alveolar epithelium by transferring-catalase conjugate. Biochim Biophys Acta 1996; 1315:21-8. (Pubitemid 26047210)
46. Nakamura S, Shibuya M, Nakashima H, et al. Involvement of oxidative stress on corneal epithelial alterations in a blink-suppressed dry eye. Invest Ophthalmol Vis Sci 2007; 48:1552-8. (Pubitemid 351261338)
47. Brown EL, Xue Q, Jiang ZD, Xu Y, DuPont HL. Pretreatment of epithelial cells with rifaximin alters attachment and internalization profiles. Antimicrob Agents Chemother 2010; 54:388-96.
48. Cirioni O, Silvestri C, Ghiselli R, et al. Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis. Crit Care Med 2009; 37:1403-7.
49. Cirioni O, Silvestri C, Ghiselli R, et al. Protective effects of the combination of α-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. J Antimicrob Chem 2008; 62:1332-8.
50. Ziglam HM, Baldwin DR, Daniels I, Andrews JM, Finch RG. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 2002; 50:1011-5. (Pubitemid 36032825)